Molecule
Methylprednisolone is a corticosteroid indicated in conditions. It is available as tablets, powder for injection and injectable suspension for intramuscular, intravenous and oral use. MedsAcross supplies Methylprednisolone for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
Methylprednisolone tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice, synthetic analogs may be used in conjunction with mineralocorticoids where applicable, in infancy, mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.
Source: US FDA prescribing information
The initial dosage of methylprednisolone tablets may vary from 4 mg to 48 mg of methylprednisolone per day, depending on the specific disease entity being treated. In situations of less severity, lower doses will generally suffice, while in selected patients, higher initial doses may be required. The initial dosage should be maintained or adjusted until a satisfactory response is noted. If after a reasonable period of time there is a lack of satisfactory clinical response, methylprednisolone tablets should be discontinued and the patient transferred to other appropriate therapy. IT SHOULD BE EMPHASIZED THAT DOSAGE REQUIREMENTS ARE VARIABLE AND MUST BE INDIVIDUALIZED ON THE BASIS OF THE DISEASE UNDER TREATMENT AND THE RESPONSE OF THE PATIENT.
Source: US FDA prescribing information
Systemic fungal infections and known hypersensitivity to components.
Source: US FDA prescribing information
In patients on corticosteroid therapy subjected to unusual stress, increased dosage of rapidly acting corticosteroids before, during, and after the stressful situation is indicated. Immunosuppression and Increased Risk of Infection Corticosteroids, including methylprednisolone, suppress the immune system and increase the risk of infection with any pathogen, including viral, bacterial, fungal, protozoan, or helminthic pathogens. Corticosteroids can: • Reduce resistance to new infections • Exacerbate existing infections • Increase the risk of disseminated infections • Increase the risk of reactivation or exacerbation of latent infections • Mask some signs of infection Corticosteroid-associated infections can be mild but can be severe and at times fatal. The rate of infectious complications increases with increasing corticosteroid dosages.
Source: US FDA prescribing information
Fluid and Electrolyte Disturbances • Sodium retention • Congestive heart failure in susceptible patients • Hypertension • Fluid retention • Potassium loss • Hypokalemic alkalosis Musculoskeletal • Muscle weakness • Loss of muscle mass • Steroid myopathy • Osteoporosis • Tendon rupture, particularly of the Achilles tendon • Vertebral compression fractures • Aseptic necrosis of femoral and humeral heads • Pathologic fracture of long bones Gastrointestinal • Peptic ulcer with possible perforation and hemorrhage • Pancreatitis • Abdominal distention • Ulcerative esophagitis Increases in alanine transaminase (ALT, SGPT), aspartate transaminase (AST, SGOT), and alkaline phosphatase have been observed following corticosteroid treatment. These changes are usually small, not associated with any clinical syndrome, and reversible upon discontinuation.
Source: US FDA prescribing information
The pharmacokinetic interactions listed below are potentially clinically important. Mutual inhibition of metabolism occurs with concurrent use of cyclosporine and methylprednisolone, therefore, it is possible that adverse events associated with the individual use of either drug may be more apt to occur. Convulsions have been reported with concurrent use of methylprednisolone and cyclosporine. Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increases in methylprednisolone dose to achieve the desired response. Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of methylprednisolone and thus decrease its clearance. Therefore, the dose of methylprednisolone should be titrated to avoid steroid toxicity.
Source: US FDA prescribing information
Store at controlled room temperature 20° to 25°C (68° to 77°F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
49 presentations of Methylprednisolone, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Methylprednisolone 4 mg tabletOralGeneric name | — | US FDA | Available on request |
| Solu-medrol 125 mg/2 mL powder for injectionIntramuscular, intravenous | Pharmacia & Upjohn | US FDA | Available on request |
| Methylprednisolone 16 mg tabletOralGeneric name | — | US FDA | Available on request |
| Methylprednisolone 32 mg tabletOralGeneric name | — | US FDA | Available on request |
| Methylprednisolone 8 mg tabletOralGeneric name | — | US FDA | Available on request |
| Solu-medrol 40 mg/mL powder for injectionIntramuscular, intravenous | Pharmacia & Upjohn | US FDA | Available on request |
| Methylprednisolone 125 mg/2 mL powder for injectionIntramuscular, intravenousGeneric name | — | US FDA | Available on request |
| Methylprednisolone 80 mg/1 mL injectable suspensionIntra-articular, intralesional, intramuscular, soft tissueGeneric name | — | US FDA | Available on request |
| Methylprednisolone 40 mg/1 mL injectable suspensionIntra-articular, intralesional, intramuscular, intrasynovial, soft tissueGeneric name | — | US FDA | Available on request |
| Methylprednisolone 40 mg/mL powder for injectionIntramuscular, intravenousGeneric name | — | US FDA | Available on request |
| Depo-Medrol 40 mg/1 mL injectable suspensionIntra-articular, intralesional, intramuscular, soft tissue | Pharmacia & Upjohn | US FDA | Available on request |
| Methylprednisolone 125 mg powder for injectionIntramuscular, intravenousGeneric name | — | US FDA | Available on request |
| Depo-Medrol 80 mg/1 mL injectable suspensionIntra-articular, intralesional, intramuscular, soft tissue | Pharmacia & Upjohn | US FDA | Available on request |
| Methylprednisolone 40 mg powder for injectionIntramuscular, intravenousGeneric name | — | US FDA | Available on request |
| Depo-Medrol 400 mg/10 mL injectable suspensionIntralesional, intramuscular, intrasynovial, soft tissue | Pharmacia & Upjohn | US FDA | Available on request |
| Depo-Medrol 400 mg/5 mL injectable suspensionIntralesional, intramuscular, intrasynovial, soft tissue | Pharmacia & Upjohn | US FDA | Available on request |
| Methylprednisolone 400 mg/10 mL injectable suspensionIntra-articular, intralesional, intramuscular, intrasynovial, soft tissueGeneric name | — | US FDA | Available on request |
| Methylprednisolone 400 mg/5 mL injectable suspensionIntra-articular, intralesional, intramuscular, intrasynovial, soft tissueGeneric name | — | US FDA | Available on request |
| Methylprednisolone 125 mg/2 mL injectionIntramuscular, intravenousGeneric name | — | US FDA | Available on request |
| Methylprednisolone 200 mg/5 mL injectable suspensionIntra-articular, intralesional, intramuscular, intrasynovial, soft tissueGeneric name | — | US FDA | Available on request |
| Methylprednisolone 500 mg powder for injectionIntramuscular, intravenousGeneric name | — | US FDA | Available on request |
| Depo-Medrol 200 mg/5 mL injectable suspensionIntralesional, intramuscular, intrasynovial, soft tissue | Pharmacia & Upjohn | US FDA | Available on request |
| Depo-Medrol 40 mg/1 mL injectable suspensionIntralesional, intramuscular, intrasynovial, soft tissue | Pharmacia & Upjohn | US FDA | Available on request |
| Medrol 4 mg tabletOral | Pharmacia & Upjohn | US FDA | Available on request |
| Methylprednisolone 1 g powder for injectionIntramuscular, intravenousGeneric name | — | US FDA | Available on request |
| Methylprednisolone 200 mg/5 mL injectable suspensionIntralesional, intramuscular, intrasynovial, soft tissueGeneric name | — | US FDA | Available on request |
| Methylprednisolone 40 mg/1 mL injectable suspensionIntralesional, intramuscular, intrasynovial, soft tissueGeneric name | — | US FDA | Available on request |
| Methylprednisolone 400 mg/10 mL injectable suspensionIntralesional, intramuscular, intrasynovial, soft tissueGeneric name | — | US FDA | Available on request |
| Methylprednisolone 400 mg/10 mL injectable suspensionIntra-articular, intralesional, intramuscular, soft tissueGeneric name | — | US FDA | Available on request |
| Methylprednisolone 400 mg/5 mL injectable suspensionIntralesional, intramuscular, intrasynovial, soft tissueGeneric name | — | US FDA | Available on request |
| Methylprednisolone 400 mg/5 mL injectable suspensionIntra-articular, intralesional, intramuscular, soft tissueGeneric name | — | US FDA | Available on request |
| Methylprednisolone 80 mg/1 mL injectable suspensionIntralesional, intramuscular, intrasynovial, soft tissueGeneric name | — | US FDA | Available on request |
| Solu-medrol 1 g/8 mL powder for injectionIntramuscular, intravenous | Pharmacia & Upjohn | US FDA | Available on request |
| Solu-medrol 1 g/mL powder for injectionIntramuscular, intravenous | Pharmacia & Upjohn | US FDA | Available on request |
| Depo-Medrol 100 mg/5 mL injectable suspensionIntralesional, intramuscular, intrasynovial, soft tissue | Pharmacia & Upjohn | US FDA | Available on request |
| Medrol 16 mg tabletOral | Pharmacia & Upjohn | US FDA | Available on request |
| Medrol 2 mg tabletOral | Pharmacia & Upjohn | US FDA | Available on request |
| Medrol 8 mg tabletOral | Pharmacia & Upjohn | US FDA | Available on request |
| Methylprednisolone 1 g/16 mL injectionIntramuscular, intravenousGeneric name | — | US FDA | Available on request |
| Methylprednisolone 2 g powder for injectionIntramuscular, intravenousGeneric name | — | US FDA | Available on request |
| Methylprednisolone 2 g/30.6 mL powder for injectionIntramuscular, intravenousGeneric name | — | US FDA | Available on request |
| Methylprednisolone 2 mg tabletOralGeneric name | — | US FDA | Available on request |
| Methylprednisolone 40 mg/1 mL injectionIntramuscular, intravenousGeneric name | — | US FDA | Available on request |
| Methylprednisolone 40 mg/1 mL injectable suspensionIntra-articular, intralesional, intramuscular, soft tissueGeneric name | — | US FDA | Available on request |
| Methylprednisolone 500 mg/4 mL powder for injectionIntramuscular, intravenousGeneric name | — | US FDA | Available on request |
| Methylprednisolone 500 mg/8 mL injectionIntramuscular, intravenousGeneric name | — | US FDA | Available on request |
| Solu-medrol 2 g/30.6 mL powder for injectionIntramuscular, intravenous | Pharmacia & Upjohn | US FDA | Available on request |
| Solu-medrol 500 mg/mL powder for injectionIntramuscular, intravenous | Pharmacia & Upjohn | US FDA | Available on request |
| Methylprednisolone 125 mg/2 mL injectionIntravascular, intravenousGeneric name | — | US FDA | Available on request |
3 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 24 October 1957 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Conditions linked to Methylprednisolone in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 49 presentations of Methylprednisolone and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 3 brand names for Methylprednisolone, including Depo-Medrol, Medrol, Solu-medrol.
Yes. The US FDA first approved Methylprednisolone on 24 October 1957, according to Drugs@FDA.
No listed presentation of Methylprednisolone is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Methylprednisolone is classified under ATC code D07AA01 (Methylprednisolone).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.